Uzi Gileadi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1124390/publications.pdf

Version: 2024-02-01

21 papers	1,897 citations	623734 14 h-index	752698 20 g-index
24 all docs	24 docs citations	24 times ranked	2163 citing authors

#	Article	IF	Citations
1	Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature, 1990, 346, 362-365.	27.8	1,174
2	Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. Nature Immunology, 2017, 18, 762-770.	14.5	147
3	Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. Journal of Immunology, 2017, 199, 2631-2638.	0.8	96
4	Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. OncoImmunology, 2016, 5, e1068493.	4.6	68
5	Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med, 2021, 2, 164-179.e12.	4.4	53
6	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. British Journal of Cancer, 2020, 123, 1089-1100.	6.4	51
7	Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells. Cancer Research, 2016, 76, 6193-6204.	0.9	45
8	Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses. OncoImmunology, 2020, 9, 1738813.	4.6	37
9	NOD2 and TLR2 Signal via TBK1 and PI31 to Direct Cross-Presentation and CD8 T Cell Responses. Frontiers in Immunology, 2019, 10, 958.	4.8	31
10	Cell identity and nucleo-mitochondrial genetic context modulate OXPHOS performance and determine somatic heteroplasmy dynamics. Science Advances, 2020, 6, eaba5345.	10.3	31
11	Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1999, 29, 2213-2222.	2.9	27
12	Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23671-23681.	7.1	21
13	PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses. Frontiers in Immunology, 2021, 12, 641703.	4.8	21
14	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. BMJ Open, 2021, 11, e050725.	1.9	21
15	Chromatin accessibility governs the differential response of cancer and TÂcells to arginine starvation. Cell Reports, 2021, 35, 109101.	6.4	20
16	Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cellâ€“mediated toxicity against glioblastoma. Neuro-Oncology, 2022, 24, 2093-2106.	1.2	18
17	Nonâ€glycosidic compounds can stimulate both human and mouse iNKT cells. European Journal of Immunology, 2016, 46, 1224-1234.	2.9	14
18	Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1₁₅₇₋₁₆₅tumor-specific peptide. , 2021, 9, e002544.		9

#	Article	IF	Citations
19	Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells. Cancer Immunology Research, 2020, 8, 685-697.	3.4	6
20	ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression. Molecular Cancer Research, 2021, 19, 1957-1969.	3.4	4
21	Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action. MAbs, 2020, 12, 1801230.	5.2	2